Q-Line Biotech NSE SME IPO review

The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables.
It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments.
As the company has no listed peers, it is trying to extract fancy price for its IPO.
Based on its overall financial data, the issue appears fully priced.
Well-informed investors may park moderate funds for long term.

About Company

Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges.

The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of the Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

QBL’s key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipment’s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc.

It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for its certain Class of Reagent & equipment’s and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, it undertakes the manufacturing of these Reagent and equipment’s and devices as per the technical collaboration and specifications provided by the partners or companies.

With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2026, the company employed 19 personnel at R&D laboratories, which constituted 5.25% of its total permanent employee strength. As of March 31, 2026, it had 362 employees on its payroll and additional 223 contract employees in various departments.

Issue Details / Capital History

The company is coming out with its maiden book building route IPO of 6253200 equity shares of Rs. 10 each to mobilize Rs. 214.48 cr. at the upper cap. The company has announced a price band of Rs. 326 - Rs. 343 per share. The minimum application to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on May 21, 2026, and will close on May 25, 2026. The IPO constitute 26.81% of the post-IPO paid-up capital of the company. The shares will be listed on NSE SME Emerge. From the net proceeds of the IPO, it will utilize Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for repayment/prepayment of certain borrowings, and the rest for general corporate purposes.

The company raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in May 2026, at Rs. 343 per share.

The IPO is jointly lead managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the issue. HEM group’s Hem Finlease Pvt. Ltd., is the market maker as well as a syndicate member.

The company has issued initial equity capital at par value. It raised further equity shares in the price range of Rs. 125 – Rs. 417 between March 2019 and May 2026. It has also issued bonus shares in the ratio of 2 for 1 in March 2016, and 9 for 1 in August 2025. The average cost of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.

Post-IPO, company’s current paid-up equity capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based on the upper band of the IPO pricing, the company is looking for a market cap of Rs. 800.16 cr.

IPO Lead Managers & Registrar

Financial Performance

On the financial performance front, for the last three fiscals, the company has (on a consolidated basis) posted total income/ net profit, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a net profit of Rs. 38.69 cr. on a total income of Rs. 236.50 cr. Though it posted growth in its top lines for the reported periods, its bottom line posted inconsistency. For FY25, it posted lower net profit of Rs. 28.13 cr., and for 9M-FY26, though the top line is Rs, 236.50 cr. it posted bumper profit of Rs. 38.69 cr. in a pre-IPO period, that not only raise eyebrows, but also concern over its sustainability going forward. Despite higher other income for FY25, it marked lower net following extra-ordinary item of Rs. 16.97 cr. Its contingent liability stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its overall borrowings of Rs. 242.57 cr. as of December 31, 2025, raise concern.

For the last two fiscals, the company has reported an average EPS of Rs. 25.00, and an average RoNW of 23.17%. The issue is priced at a P/BV of 2.44 based on its NAV of Rs. 140.81 per share as of December 31, 2025, but its post-IPO NAV data is missing from the offer documents.

If we attribute FY26 super earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 15.51, and based on FY25 earnings, the P/E stands at 28.44. The issue appears fully priced, based on its bumper earnings for 9M-FY26, which may not be sustained.

For the reported periods, the company has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of 22.14%, 19.25%, 17.66%, 13.32%, respectively, for referred periods.

All amounts in Indian Rupees crores

Period Ended	Revenue	Expense	PAT	Assets
2023	₹184.81	₹154.97	₹32.10	₹251.58
2024	₹206.45	₹175.85	₹34.44	₹339.25
2025	₹322.58	₹261.43	₹28.13	₹455.49
Dec 2025	₹236.50	₹186.96	₹38.69	₹561.34

Dividend Policy

The company has not paid any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy, based on its financial performance and future prospects.

Comparison with Listed Peers - for Fiscal 2025

As per the offer document, the company has no listed peers to compare with.

Name of the Company	Face Value (₹)	EPS basic (₹)	EPS Diluted (₹)	RONW (%)	P/E Ratio	NAV (₹)
Powerica Limited	5	15.26	15.26	15.37 %	24.45	99.76
Listed Peers
Cummins India Limited	2	72.15	72.15	26.45%	64.13	272.78
Kirloskar Oil Engines Limited	2	33.71	33.60	15.85%	43.24	212.60
NTPC Green Energy Limited	10	0.67	0.67	2.58%	129.40	21.88
Acme Solar Holdings Limited	2	4.55	4.53	5.59%	50.74	74.54
Adani Green Energy Limited	10	8.37	8.37	11.90%	101.53	76.62

Disclaimer: Above table shows earnings and P/E ratio as of 2025-26

Merchant Banker's Track Record

The two merchant bankers associated with this issue have handled 79 issues in the past three years, out of which 8 issues closed below the issue price on listing date.

Conclusion - Apply for medium to long term

QBL is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables. It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments. As the company has no listed peers, it is trying to extract fancy price for its IPO. Based on its overall financial data, the issue appears fully priced. Well-informed investors may park moderate funds for long term.

Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.

He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.

Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.

FAQ Accordion

Q-Line Biotech IPO FAQs

1. What is Q-Line Biotech IPO? ⌄

Q-Line Biotech IPO is SME IPO. The company is going to raise ₹214 Crores via IPO. The issue is priced at ₹326 to ₹343 per equity share. The IPO is to be listed on NSE SME.

2. When Q-Line Biotech IPO will open for subscription? ⌄

The IPO is to open on May 21, 2026 for QIB, NII, and Retail Investors. The IPO will close on May 25,2026.

3. What is Q-Line Biotech IPO Investors Portion? ⌄

The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.

4. How to Apply the Q-Line Biotech IPO? ⌄

You can apply for Q-Line Biotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

5. What is Q-Line Biotech IPO Issue Size? ⌄

Q-Line Biotech IPO issue size is ₹214 crores.

6. What is Q-Line Biotech IPO Price Band? ⌄

Q-Line Biotech IPO Price Band is ₹326 to ₹343.

7. What is Q-Line Biotech IPO Lot Size? ⌄

The minimum bid is 800 Shares with ₹2,74,400 amount.

8. What is the Q-Line Biotech IPO Allotment Date? ⌄

Q-Line Biotech IPO allotment date is May 26,2026.

9. What is the Q-Line Biotech IPO Listing Date? ⌄

Q-Line Biotech IPO listing date is May 29, 2026. The IPO is to list on NSE SME.

IREDA IPO Date, Review, Price, Allotment Details

By Jagat Joshi
November 29, 2023

IREDA IPO Details: IREDA IPO date is fixed, the IPO is to hit the market on November 21 and will close on November 23. IREDA IPO to raise around ₹2150 crores via IPO that comprises fresh issue of ₹1290 and offer for sale up to 268,776,471 Shares of ₹10 each. The retail quota is 35%, QIB is 50%, and HNI is 15%.

Indian Renewable Energy Development Agency (IREDA) is a wholly owned Government of India (“GoI”) enterprise under the administrative control of the Ministry of New and Renewable Energy (the “MNRE”). The Company was notified as a“Public Financial Institution” (“PFI”) under Section 4A of the Companies Act, 1956 by the Department of Company Affairs, Ministry of Law, Justice and Company Affairs, Government of India on October 17, 1995 and is registered with the Reserve Bank of India (the “RBI”) as a Systemically Important Non-Deposit-taking Non-Banking Finance Company (a “NBFC-ND-SI”), with Infrastructure Finance Company (“IFC”) status.

IREDA is a financial institution with over 36 years of experience in the business of promoting, developing, and 241 extending financial assistance for new and renewable energy (“RE”) projects, and energy efficiency and conservation (“EEC”) projects. They provide a comprehensive range of financial products and related services, from project conceptualization to post-commissioning, for RE projects and other value chain activities, such as equipment manufacturing and transmission.

As of June 30, 2023, they had a diversified portfolio of Term Loans Outstanding, amounting to ₹472,066.63 million, as outlined in “Competitive Strengths – Track record of growth, geared towards high-quality assets, diversified asset book, and stable profitability” as per the DRHP filed. The company financed projects across multiple RE sectors such as solar power, wind power, hydropower, transmission, biomass including bagasse and industrial co-generation, waste-to-energy, ethanol, compressed biogas, hybrid RE, EEC, and green-mobility. They also offer financial products and schemes for new and emerging RE technologies such as biofuel, green hydrogen and its derivatives, battery energy storage systems, fuel cells, and hybrid RE projects. They offer a comprehensive suite of financial products and services including various fund-based and non fund-based products. Some of our key fund-based products for RE developers are long-term, medium-term, and short-term loans (for projects, manufacturing, and equipment financing), top-up loans, bridge loans, takeover financing, and loans against securitization of future cash flows. They also provide line of credit to other NBFCs for on-lending to RE and EEC projects.

Objects of the Issue

Gross proceeds of the Fresh Issue
Less: Fresh Issue related expenses*
Net Proceeds

IREDA IPO Review (Apply or Not)

Apply

Brokerage Firm IPO Review

BP Equities (BP Wealth): Apply
Choice Equity Broking Pvt Ltd: Apply
Nirmal Bang: Apply
Reliance Securities: Apply
Swastika Investmart Ltd: Apply

IREDA IPO Date & Price Band Details

IPO Open:	November 21, 2023
IPO Close:	November 23, 2023
IPO Size:	Approx ₹2150 Crores
Fresh Issue:	Approx ₹1290 Crores
Offer for Sale:	Approx 268,776,471 shares
Face Value:	₹10 Per Equity Share
IPO Price Band:	₹30 to ₹32 Per Share
IPO Listing on:	BSE & NSE
Retail Quota:	35%
QIB Quota:	50%
NII Quota:	15%
Discount:	N/A
DRHP Draft Prospectus:	Click Here
RHP Draft Prospectus:	Click Here
Anchor Investors List:	Click Here

IREDA IPO Market Lot

The IREDA IPO minimum market lot is 460 shares with ₹14,720 application amount. The retail investors can apply up-to 13 lots with 5980 shares or ₹191,360 amount.

Application	Lot Size	Shares	Amount
Retail Minimum	1	460	₹14,720
Retail Maximum	13	5980	₹191,360
S-HNI Minimum	14	6,440	₹206,080
B-HNI Minimum	68	31,280	₹1,000,960

IREDA IPO Allotment & Listing Dates

The IREDA IPO date is November 21 and the close date is November 23. The IREDA IPO allotment will be finalized on November 25 and the IPO listing on November 29

Anchor Investors Allotment:	November 20, 2023
IPO Open Date:	November 21, 2023
IPO Close Date:	November 23, 2023
Basis of Allotment:	November 25, 2023
Refunds:	November 26, 2023
Credit to Demat Account:	November 28, 2023
IPO Listing Date:	November 29, 2023

You can check IPO subscription status and IPO allotment status on their respective pages.

IREDA IPO Form

How to apply for the IREDA IPO? You can apply for IREDA IPO via ASBA available in your bank account. Just go to the online bank login and apply via your bank account by selecting the IREDA IPO in the Invest section. The other option is you can apply for IREDA IPO via IPO forms downloaded via NSE and BSE. Check out the IREDA forms – Click BSE Forms & NSE Forms blank IPO forms download, fill, and submit in your bank or with your broker.

IREDA Company Financial Report

₹ in Crores
Year	Revenue	Expense	PAT
2021	₹2658	₹2088	₹346.38
2022	₹2874	₹2040	₹633.53
2023	₹3483	₹2344	₹864.63
2024 3M	₹1143	₹704	₹294.58

IREDA IPO Valuation – FY2023

Check IREDA IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.

Earning Per Share (EPS):	₹1.29 per Equity Share
Price/Earning P/E Ratio:	N/A
Return on Net Worth (RoNW):	15.43%
Net Asset Value (NAV):	₹25.98 per Equity Share

Peer Group

REC Limited
Power Finance Corporation

Company Promoters

THE PRESIDENT OF INDIA, ACTING THROUGH THE MINISTRY OF NEW AND RENEWABLE ENERGY, GOVERNMENT OF INDIA

IREDA IPO Registrar

Link Intime India Private Limited
Telephone: +91 81 0811 4949
E-mail: indianrenergy@linkintime.co.in
Website: www.linkintime.co.in

IREDA IPO Allotment Status Check

Check IREDA IPO allotment status on Linkintime website allotment URL. Click Here

IREDA IPO Lead Managers aka Merchant Bankers

BOB Capital Markets Limited
SBI Capital Markets Limited
IDBI Capital Markets & Securities Limited

Company Address

IREDA Limited
India Habitat Centre, East Court,
Core 4A, 1stFloor, Lodhi Road,
New Delhi –110003, India
Telephone: +91 11 24682214
E-mail: equityinvestor2023@ireda.in
Website: www.ireda.in

IREDA IPO FAQs

What is IREDA IPO?

IREDA IPO is a main-board IPO. They are going to raise ₹2150 Crores via IPO. The issue is priced at ₹30 to ₹32 pr equity share. The IPO is to be listed on BSE & NSE.

When IREDA IPO will open?

The IPO is to open on November 21, 2023 for QIB, NII, and Retail Investors.

What is IREDA IPO Investors Portion?

The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.

How to Apply the IREDA IPO?

You can apply for IREDA IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

How to Apply the IREDA IPO through Zerodha?

Log in to Console in Zerodha Website or in Application. Go to Portfolio and Click on IPO. You will see the IPO Name “IREDA”. Click on Bid Button. Enter your UPI ID, Quantity, and Price. Submit IPO Application Form. Now go to your UPI App on Net Banking or BHIM App to Approve the mandate. Open Demat Account with Zerodha.

How to Apply the IREDA IPO through Upstox?

Log in to the Upstox Application with your credentials. Select the IPO. You will see the IPO Name “IREDA”. Click on Bid Button. Confirm your Application. Now go to your UPI App on Net Banking or BHIM App to Approve the mandate. Open Demat Account with Upstox.

How to Apply the IREDA IPO through Paytm Money?

Log in to Paytm Money Application with your credentials. Select the IPO. You will see the IPO Name “IREDA”. Click on Bid Button. Confirm your Application. Now go to your UPI App on Net Banking or BHIM App to Approve the mandate. Open Demat Account with Paytm Money.

What is IREDA IPO Size?

IREDA IPO size is ₹2150 crores.

What is IREDA IPO Price Band?

IREDA IPO Price Band is ₹30 to ₹32.

What is the IREDA IPO Allotment Date?

IREDA IPO allotment date is November 25, 2023.

What is the IREDA IPO Listing Date?

IREDA IPO listing date is November 29, 2023. The IPO is to list on BSE and NSE.

Note: The IREDA IPO price band and date are officially announced. The IPO grey market premium (IREDA IPO Premium) will be added to the IPO grey market page as it will start).

Follow IPO Watch for the Upcoming IPO news and their reviews, also keep following us on Twitter, Facebook, and Instagram. For our latest videos, subscribe to our YouTube channel.

Jagat Joshi

Founder of IPOWatch, brings nearly 15 years of experience in IPO analysis and market research. He provides complete coverage of upcoming IPOs, subscription trends, grey market premiums (GMP), and post-listing performance, along with easy-to-understand reviews, insights, and analysis. In his working journey, he has worked with various platforms and received expertise in stock market analysis and primary markets.